EUCAST expert rules in antimicrobial susceptibility testing

Clinical Microbiology and Infection

Volumn 19, Issue 2, 2013, Pages 141-160

  Leclercq, R ^a,b   Canton R ^b,c,d   Brown, D F J ^d   Giske, C G ^b,d,e   Heisig, P ^b,f   Macgowan, A P ^d,g   Mouton, J W ^d,h   Nordmann, P ^b,i   Rodloff, A C ^d,j   Rossolini, G M ^b,k   Soussy, C J ^d,l   Steinbakk, M ^d,m   Winstanley, T G ^b,n   Kahlmeter, G ^d,o  

^a CHU CÔTE DE NACRE   (France)

^b EUCAST Subcommittee on Expert Rules   (Sweden)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d EUCAST Steering Committee   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF HAMBURG   (Germany)

^g SOUTHMEAD HOSPITAL   (United Kingdom)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ BICÊTRE HOSPITAL   (France)

^j UNIVERSITY OF LEIPZIG   (Germany)

^k Sezione di Microbiologia   (Italy)

^l HENRI MONDOR HOSPITAL   (France)

^m NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

ⁿ ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^o CENTRAL HOSPITAL   (Sweden)

more..

Author keywords

Antimicrobial susceptibility testing; Breakpoints; EUCAST; Expert rules; Interpretive reading

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN; AMPICILLIN; AZTREONAM; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; DALFOPRISTIN; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; GLYCOPEPTIDE; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; NALIDIXIC ACID; NETILMICIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINUPRISTIN; ROXITHROMYCIN; STREPTOMYCIN; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER; ADVISORY COMMITTEE; ALPHA HEMOLYTIC STREPTOCOCCUS; ANAEROBE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTEROIDES; BETA HEMOLYTIC STREPTOCOCCUS; CAMPYLOBACTER FETUS; CAMPYLOBACTER JEJUNI; CITROBACTER FREUNDII; CITROBACTER KOSERI; CLOSTRIDIUM DIFFICILE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CORYNEBACTERIUM; ENTEROBACTER AEROGENES; ENTEROBACTERIACEAE; ENTEROCOCCUS; ENTEROCOCCUS AVIUM; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HAFNIA ALVEI; KLEBSIELLA; LACTOBACILLUS; LEUCONOSTOC; LISTERIA MONOCYTOGENES; MORAXELLA CATARRHALIS; MORGANELLA MORGANII; NEISSERIA; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEACEAE; PROTEUS MIRABILIS; PROTEUS PENNERI; PROTEUS VULGARIS; PROVIDENCIA RETTGERI; PROVIDENCIA STUARTII; PSEUDOMONAS AERUGINOSA; REVIEW; SERRATIA INFECTION; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS CAPITIS; STAPHYLOCOCCUS SAPROPHYTICUS; STAPHYLOCOCCUS XYLOSUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; YERSINIA ENTEROCOLITICA; YERSINIA PSEUDOTUBERCULOSIS;

EID: 84873525652     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03703.x     Document Type: Review

References (123)

1. Winstanley T, Courvalin P. Expert systems in clinical microbiology. Clin Microbiol Rev 2011; 24: 515-556.
2. Courvalin P. Interpretive reading of antimicrobial susceptibility tests. ASM News 1992; 58: 368-375.
3. Courvalin P. Interpretive reading of in vitro antibiotic susceptibility tests (the antibiogramme). Clin Microbiol Infect 1996; 2 (suppl 1): S26-S34.
4. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 2001; 48 (suppl 1): 87-102.
5. Macgowan AP, BSAC Working Parties on Resistance Surveillance. Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 2008; 62 (suppl 2): ii105-ii114.
6. Vedel G, Peyret M, Gayral JP, Millot P. Evaluation of an expert system linked to a rapid antibiotic susceptibility testing system for the detection of β-lactam resistance phenotypes. Res Microbiol 1996; 147: 297-309.
7. Livermore DL, Struelens, M, Amorim J et al. Multicentre evaluation of the VITEK 2 advanced expert system for interpretive reading of antimicrobial resistance tests. J Antimicrob Chemother 2002; 49: 289-300.
8. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.
9. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010; 54: 969-976.
10. Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol Rev 2008; 32: 361-385.
11. Pagès JM, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 2008; 6: 893-903.
12. Poole K. Efflux pumps as antimicrobial resistance mechanisms. Ann Med 2007; 39: 162-176.
13. Page MG. Anti-MRSA β-lactams in development. Curr Opin Pharmacol 2006; 5: 480-485.
14. Brown DF. Detection of methicillin/oxacillin resistance in staphylococci. J Antimicrob Chemother 2001; 48 (suppl 1): 65-70.
15. Chambers HF, Sachdeva M, Kennedy S. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of β-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis 1990; 162: 705-710.
16. Montanari MP, Massidda O, Mingoia M, Varaldo PE. Borderline susceptibility to methicillin in Staphylococcus aureus: a new mechanism of resistance?Microb Drug Resist 1996; 2: 257-260.
17. Kimura K, Suzuki S, Wachino J et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 2008; 52: 2890-2897.
18. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. Clin Infect Dis 2004; 11: 1526-1534.
19. File TM Jr. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect 2006; 12 (suppl 3): 31-41.
20. Nagai K, Davies TA, Jacobs MR, Appelbaum PC. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother 2002; 5: 1273-1280.
21. Fontana R, Ligozzi M, Pittaluga F, Satta G. Intrinsic penicillin resistance in enterococci. Microb Drug Resist 1996; 2: 209-213.
22. Leclercq R. Enterococci acquire new kinds of resistance. Clin Infect Dis 1997; 24 (suppl 1): S80-S84.
23. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-878.
24. Livermore DM, Brown DF. Detection of β-lactamase-mediated resistance. J Antimicrob Chemother 2001; 48 (suppl 1): 59-64.
25. Drieux L, Brossier F, Sougakoff W, Jarlier V. Phenotypic detection of extended-spectrum β-lactamase production in Enterobacteriaceae: review and bench guide. Clin Microbiol Infect 2008; 14 (suppl 1): 90-103.
26. Kahlmeter G. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae-EUCAST and CLSI breakpoints. Clin Microbiol Infect 2008; 14 (suppl 1): 169-174.
27. MacGowan A. Breakpoints for extended-spectrum β-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations. Clin Microbiol Infect 2008; 14 (suppl 1): 166-168.
28. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hsueh PR. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study. Int J Antimicrob Agents 2010; 36: 293-294.
29. Bin C, Hui W, Renyuan Z et al. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 2006; 56: 351-357.
30. Endimiani A, Paterson DL. Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum β-lactamases. Semin Respir Crit Care Med 2007; 28: 646-655.
31. Maglio D, Ong C, Banevicius MA, Geng Q, Nightingale CH, Nicolau DP. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-β-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother 2004; 48: 1941-1947.
32. Wong-Beringer A, Hindler J, Loeloff M et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002; 34: 135-146.
33. Paterson DL, Ko WC, Von Gottberg A et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206-2212.
34. Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN, SENTRY Antimicrobial Surveillance Program. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006; 54: 231-236.
35. Potz NA, Colman M, Warner M, Reynolds R, Livermore DM. False-positive extended-spectrum β-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 β-lactamase. J Antimicrob Chemother 2004; 53: 545-547.
36. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm?Clin Microbiol Rev 2005; 18: 306-325.
37. Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol 2007; 2: 501-512.
38. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22.
39. Woodford N, Dallow J, Hill RLR et al. Mechanisms of ertapenem resistance among Klebsiella and Enterobacter submitted in the United Kingdom to a reference laboratory. Int J Antimicrob Agents 2007; 29: 456-459.
40. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009; 53: 1868-1873.
41. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?Clin Microbiol Infect 2011; 17: 1135-1141.
42. Tato M, Morosini M, García L, Albertí S, Coque MT, Cantón R. Carbapenem heteroresistance in VIM-1-producing Klebsiella pneumoniae isolates belonging to the same clone: consequences for routine susceptibility testing. J Clin Microbiol 2010; 48: 4089-4093.
43. Livermore DM. Has the era of untreatable infections arrived?J Antimicrob Chemother 2009; 64 (suppl 1): i29-i36.
44. Gavin PJ, Suseno MT, Thomson RB Jr et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006; 50: 2244-2247.
45. Rodríguez-Baño J, Navarro MD, Romero L et al. Bacteremia due to extended spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis, 2006; 43: 1407-1414.
46. Chow JW, Fine MJ, Shlaes DM et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-590.
47. Schwaber MJ, Graham CS, Sands BE, Gold HS, Carmeli Y. Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother 2003; 47: 1882-1886.
48. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007; 20: 368-389.
49. Ubukata K, Shibasaki Y, Yamamoto K et al. Association of amino acid substitutions in penicillin-binding protein 3 with β-lactam resistance in β-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 2001; 45: 1693-1699.
50. Morikawa Y, Kitazato M, Mitsuyama J, Mizunaga S, Minami S, Watanabe Y. In vitro activities of piperacillin against β-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 2004; 48: 1229-1234.
51. Kubota T, Higa F, Kusano N et al. Genetic analyses of β-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect Dis 2006; 59: 36-41.
52. Matic V, Bozdogan B, Jacobs MR, Ubukata K, Appelbaum PC. Contribution of β-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in β-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae. J Antimicrob Chemother 2003; 52: 1018-1021.
53. Bozdogan B, Tristram S, Appelbaum PC. Combination of altered PBPs and expression of cloned extended-spectrum β-lactamases confers cefotaxime resistance in Haemophilus influenzae. J Antimicrob Chemother 2006; 57: 747-749.
54. Tristram SG, Pitout MJ, Forward K, Campbell S, Nichols S, Davidson RJ. Characterization of extended-spectrum β-lactamase-producing isolates of Haemophilus parainfluenzae. J Antimicrob Chemother 2008; 61: 509-514.
55. Dillon JA, Yeung KH. β-Lactamase plasmids and chromosomally mediated antibiotic resistance in pathogenic Neisseria species. Clin Microbiol Rev 1989; 2: S125-S133.
56. Ropp PA, Hu M, Olesky M, Nicholas RA. Mutations in ponA, the gene encoding penicillin-binding protein 1, and a novel locus, penC, are required for high-level chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2002; 46: 769-777.
57. Olesky M, Zhao S, Rosenberg RL, Nicholas RA. Porin-mediated antibiotic resistance in Neisseria gonorrhoeae: ion, solute, and antibiotic permeation through PIB proteins with penB mutations. J Bacteriol 2006; 188: 2300-2308.
58. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34: 482-492.
59. Lewis JS, Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned?Clin Infect Dis 2005; 40: 280-285.
60. Entenza JM, Drugeon H, Glauser MP, Moreillon P. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother 1995; 39: 1419-1424.
61. Batard E, Jacqueline C, Boutoille D et al. Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus: experimental rabbit endocarditis study. Antimicrob Agents Chemother 2002; 46: 2174-2178.
62. Reig M, Fernández MC, Ballesta JP, Baquero F. Inducible expression of ribosomal clindamycin resistance in Bacteroides vulgatus. Antimicrob Agents Chemother 1992; 36: 639-642.
63. Reig M, Moreno A, Baquero F. Resistance of Peptostreptococcus spp. to macrolides and lincosamides: inducible and constitutive phenotypes. Antimicrob Agents Chemother 1992; 36: 662-664.
64. Kotra LP, Haddad J, Mobashery S. Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance. Antimicrob Agents Chemother 2000; 44: 3249-3256.
65. Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol 2006; 70: 140-150.
66. Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev 2003; 16: 430-450.
67. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007; 45: 88-94.
68. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006; 43 (suppl 2): S49-S56.
69. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57: 138-163.
70. Davies J, Wright GD. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol 1997; 5: 234-240.
71. Wright GD. Aminoglycoside-modifying enzymes. Curr Opin Microbiol 1999; 2: 499-503.
72. Azucena E, Mobashery S. Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition. Drug Resist Updat 2001; 4: 106-117.
73. Chow JW. Aminoglycoside resistance in enterococci. Clin Infect Dis 2000; 31: 586-589.
74. Thauvin C, Eliopoulos, GM, Wennersten, C, Moellering, RC Jr. Antagonistic effect of penicillin-amikacin combinations against enterococci. Antimicrob Agents Chemother 1985; 28: 78-83.
75. Martel A, Moreau N, Capmau ML, Soussy CJ, Duval J. 2′′-O-phosphorylation of gentamicin components by a Staphylococcus aureus strain carrying a plasmid. Antimicrob Agents Chemother 1977; 12: 26-30.
76. Courvalin P, Davies J. Plasmid-mediated aminoglycoside phosphotransferase of broad substrate range that phosphorylates amikacin. Antimicrob Agents Chemother 1977; 11: 619-624.
77. Benveniste R, Davies J. Enzymatic acetylation of aminoglycoside antibiotics by Escherichia coli carrying an R factor. Biochemistry 1971; 10: 1787-1796.
78. Le Goffic F, Martel A, Witchitz J. 3-N enzymatic acetylation of gentamicin, tobramycin, and kanamycin by Escherichia coli carrying an R factor. Antimicrob Agents Chemother 1974; 6: 680-684.
79. Martin P, Jullien E, Courvalin P. Nucleotide sequence of Acinetobacter baumannii aphA-6 gene: evolutionary and functional implications of sequence homologies with nucleotide-binding proteins, kinases and other aminoglycoside-modifying enzymes. Mol Microbiol 1988; 2: 615-625.
80. Shaw KJ, Hare RS, Sabatelli FJ et al. Correlation between aminoglycoside resistance profiles and DNA hybridization of clinical isolates. Antimicrob Agents Chemother 1991; 35: 2253-2261.
81. Knothe H, Kettner M, Krcmery V. R-plasmids in Providencia and Proteus rettgeri strains from Frankfurt University Hospital. In: Mituhashi S, Roswal L, Krcmery V, eds. Plasmids. Medical and theoretical aspects. Berlin: Springer-Verlag, 1977; 435-439.
82. Widermann B, Klopfer-Kaul I, Tetzloff G. Untersuchungen uber das Aminoglykosid-Antibiotika inaktivienerde enzyme AAC(6′). Infection 1979; 7: S192-S196.
83. Macinga DR, Rather PN. The chromosomal 2′-N-acetyltransferase of Providencia stuartii: physiological functions and genetic regulation. Front Biosci 1999; 4: D132-D140.
84. Chen HY, Williams JD. Transferable resistance and aminoglycoside-modifying enzymes in enterococci. J Med Microbiol 1985; 20: 187-196.
85. Smith JT. The mode of action of 4-quinolones and possible mechanisms of resistance. J Antimicrob Chemother 1986; 18 (suppl D): 21-29.
86. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41 (suppl 2): S120-S126.
87. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis 2006; 6: 629-640.
88. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797-799.
89. Robicsek A, Strahilevitz J, Jacoby GA et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat Med 2006; 12: 83-88.
90. Martínez-Martínez L, Eliecer Cano M, Manuel Rodríguez-Martínez J, Calvo J, Pascual A. Plasmid-mediated quinolone resistance. Expert Rev Anti Infect Ther 2008; 6: 685-711.
91. Rodríguez-Martínez JM, Cano ME, Velasco C, Martínez-Martínez L, Pascual A. Plasmid-mediated quinolone resistance: an update. J Infect Chemother 2011; 17: 149-182.
92. Jones ME, Visser MR, Klootwijk M, Heisig P, Verhoef J, Schmitz FJ. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linezolid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 1999; 43: 421-423.
93. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003; 47: 3222-3232.
94. Montanari MP, Tili E, Cochetti I, Mingoia M, Manzin A, Varaldo PE. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy. Microb Drug Resist 2004; 10: 209-217.
95. Helms M, Vastrup P, Gerner-Smidt P, Molbak K. Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium. Emerg Infect Dis 2002; 8: 490-495.
96. Rodríguez-Martínez JM, López L, García I, Pascual A. Characterization of a clinical isolate of Haemophilus influenzae with a high level of fluoroquinolone resistance. Antimicrob Chemother 2006; 57: 577-578.
97. Kadhiravan T, Wig N, Kapil A, Kabra SK, Renuka K, Misra A. Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella typhi. BMC Infect Dis 2005; 5: 37.
98. Slinger R, Desjardins M, McCarthy AE et al. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis, 2004; 4: 36.
99. Nathwani D, Wood MJ. Penicillins. A current review of their clinical pharmacology and therapeutic use. Drugs, 1993; 6: 866-894.
100. Karlowsky JA, Jones ME, Mayfield DC, Thornsberry C, Sahm DF. Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA. Int J Antimicrob Agents, 2002; 5: 413-426.
101. Kuriyama T, Karasawa T, Nakagawa K, Nakamura S, Yamamoto E. Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 β-lactam antibiotics. Oral Microbiol Immunol, 2002; 5: 285-289.
102. Jones ME, Draghi DC, Karlowsky JA, Sahm DF, Bradley JS. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by US hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob, 2004; 3: 3.
103. Weinstein MP, Mirrett S, Kannangara S et al. Multicenter evaluation of use of penicillin and ampicillin as surrogates for in vitro testing of susceptibility of enterococci to imipenem. J Clin Microbiol, 2004; 8: 3747-3751.
104. Ono S, Muratani T, Matsumoto T. Mechanisms of resistance to imipenem and ampicillin in Enterococcus faecalis. Antimicrob Agents Chemother, 2005; 7: 2954-2958.
105. Jarlier V, Soussy CJ, Chanal M et al. In vitro effect of piperacillin on aerobic bacteria. Variations according to the phenotypes of resistance to β-lactam antibiotics. Press Med 1986; 15: 2272-2278.
106. Thomas WJ, McReynolds JW, Mock CR, Bailey DW. Ampicillin-resistant Haemophilus influenzae meningitis. Lancet, 1974; 7852: 313.
107. Medeiros AA, O'Brien TF. Ampicillin-resistant Haemophilus influenzae type B possessing a TEM-type β-lactamase but little permeability barrier to ampicillin. Lancet, 1975; 7909: 716-719.
108. Kim IS, Ki CS, Kim S et al. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. Antimicrob Agents Chemother, 2007; 51: 453-460.
109. Fantin B, Leclercq R, Garry L, Carbon C. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrob Agents Chemother, 1997; 41: 931-935.
110. Le Goffic F, Baca B, Soussy CJ, Dublanchet A, Duval J. ANT(4′)I: a new aminoglycoside nucleotidyltransferase found in Staphylococcus aureus. Ann Microbiol (Paris), 1976; 127: 391-399.
111. Asseray N, Caillon J, Roux N et al. Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection model. Antimicrob Agents Chemother, 2002; 46: 1591-1593.
112. Mederski-Samoraj BD, Murray BE. High-level resistance to gentamicin in clinical isolates of enterococci. J Infect Dis, 1983; 147: 751-757.
113. Galimand M, Lambert T, Gerbaud G, Courvalin P. Characterization of the aac(6′)-Ib gene encoding an aminoglycoside 6′-N-acetyltransferase in Pseudomonas aeruginosa BM2656. Antimicrob Agents Chemother, 1993; 7: 1456-1462.
114. Witchitz JL. Plasmid-mediated gentamicin resistance not associated with kanamycin resistance in Enterobacteriaceae. J Antibiot, 1972; 25: 622-624.
115. Benveniste R, Davies J. R-factor mediated gentamicin resistance: a new enzyme which modifies aminoglycoside antibiotics. FEBS Lett, 1971; 14: 293-296.
116. Stein GE, Schooley S, Tyrrell KL, Citron DM, Goldstein EJ. Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob Agents Chemother, 2003; 47: 1308-1312.
117. Santos Sanches I, Mato R, de Lencastre H, Tomasz A, CEM/NET Collaborators and the International Collaborators. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Microb Drug Resist 2000; 6: 199-211.
118. Perez-Trallero E, Marimon JM, Gonzalez A, Ercibengoa M, Larruskain J. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis, 2005; 41: 560-564.
119. Urban C, Rahman N, Zhao X et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis, 2001; 184: 794-798.
120. Varon E, Houssaye S, Grondin S, Gutmann L, Groupe des Observatoires de la Resistance du Pneumocoque. Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother, 2006; 50: 572-579.
121. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med, 2002; 346: 747-750.
122. Pérez-Vázquez M, Román F, Aracil B, Cantón R, Campos J. Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations. J Clin Microbiol 2004; 42: 1185-1191.
123. Knapp JS, Fox KK, Trees DL, Whittington WL. Fluoroquinolone resistance in Neisseria gonorrhoeae. Emerg Infect Dis, 1997; 3: 33-39.